Searched over 200M research papers
10 papers analyzed
Some studies suggest that diabetes, particularly through insulin therapy and improved glycemic control, can lead to weight gain, while other studies emphasize the importance of weight management and the use of weight-beneficial medications to mitigate this effect.
6 papers analyzed
20 papers analyzed
Insulin therapy, commonly used to manage both type 1 and type 2 diabetes, is frequently associated with weight gain. This weight gain can be significant and may adversely affect cardiovascular health. The primary mechanisms include a reduction in blood glucose levels below the renal threshold without a corresponding decrease in calorie intake, increased calorie intake due to fear or experience of hypoglycemia, and the pharmacokinetic and metabolic profiles of subcutaneous insulin administration.
Intensive insulin therapy, aimed at achieving tight glycemic control, has been shown to result in more substantial weight gain compared to conventional treatment. For instance, in the Diabetes Control and Complications Trial (DCCT), subjects on intensive therapy gained significantly more weight than those on standard treatment. This weight gain was linked to improved utilization of calories due to decreased glycosuria and other mechanisms. Additionally, weight gain was more pronounced in those with higher baseline HbA1c levels and greater reductions in HbA1c during therapy.
Excessive weight gain in diabetes patients, particularly those on intensive insulin therapy, has been associated with increased cardiovascular risk factors. In the DCCT/EDIC study, participants who experienced the highest quartile of weight gain had increased cardiovascular disease (CVD) risk factors and a higher incidence of CVD events over time. Similarly, weight gain in type 2 diabetes patients has been linked to worsened glycemic control and increased risk of diabetes progression and cardiovascular complications.
Weight changes, both gain and loss, in type 2 diabetes patients have been associated with adverse cardiovascular outcomes. A cohort study and meta-analysis found that weight gain of 5% or more was linked to higher risks of total vascular complications, including macrovascular and microvascular complications. This highlights the importance of weight management in reducing cardio-metabolic risks in diabetes patients.
The potential causes of weight gain in diabetes patients include increased energy intake due to fear of hypoglycemia, reduction in glycosuria, and central effects on weight and appetite regulation. In type 1 diabetes, weight gain has also been associated with increased insulin doses and changes in insulin regimens.
Several strategies can help mitigate insulin-associated weight gain. These include increasing insulin sensitivity through diet and exercise, using adjunctive anorectic or insulin-sparing pharmacotherapies such as pramlintide or metformin, and employing insulin regimens that mimic physiological norms. Additionally, certain insulin analogs like insulin detemir have been shown to cause less weight gain compared to other insulin products.
In summary, diabetes, particularly when managed with insulin therapy, can lead to significant weight gain. This weight gain is associated with increased cardiovascular risks and can complicate diabetes management. Understanding the mechanisms behind this weight gain and implementing strategies to mitigate it are crucial for improving health outcomes in diabetes patients. Effective weight management should be an integral part of diabetes treatment strategies to enhance glycemic control and reduce morbidity and mortality.
Most relevant research papers on this topic